Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...

We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...

The following is a summary of “Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy,” ...

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

A woman with SMA type 3 became pregnant while on Spinraza treatment and gave birth to a healthy child, per a case report.

Asher Cantrell, diagnosed with SMARD 1, has received experimental gene therapy after social media support and is currently ...

Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.

Spinal muscular atrophy (SMA) is a progressive genetic neuromuscular condition ... Neurologically, the patient scores 7 points on the Hammersmith Infant Neurological Examination scale and 3 points on ...

Laminectomy is a type of spinal decompression surgery where a surgeon removes the bony arch from one or more of your spinal bones (vertebrae). This widens the space around your spine and can help ...